Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Repatha and Evenity, Tepezza and Uplizna, for example, the latter two acquired via Amgen's ~$28bn deal to acquire Horizon Therapeutics in 2023, alongside gout therapy Krystexxa, and in oncology ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $260.0 to $340.0 in the last 30 ...

Evenity, Krystexxa, and Blincyto, as well as the launch of MariTide and rocatinlimab, which are currently experimental drugs. Given Amgen's current share price of $315.6, this corresponds to a ...

Amgen Inc. (NASDAQ:AMGN ... which treats neuromyelitis optica spectrum disorder (NMOSD), are introduced. EVENITY, which targets osteoporosis in postmenopausal women, and Repatha, which addresses ...

Amgen expects key drugs like Repatha, Evenity Tezspire and oncology and rare disease drugs as well as biosimilars to drive top-line growth in 2025. However, the biosimilar erosion of Prolia/Xgeva ...

Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia, Kyprolis and Blincyto, among others. However, prices of most products ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.